Hepatitis Monthly

Published by: Kowsar

HCV Infection among Injecting Drug Users in Prishtina, Kosovo

Xhevat Jakupi 1 , Maja M. Lunar 2 , Jana Mlakar 2 , Ivana Matković 2 , Norma P. Tavakoli 3 , Beti Zafirova Ivanovska 4 , Adriana Vince 5 and Mario Poljak 2 , *
Authors Information
1 Department of Microbiology, National Institute of Public Health of Kosovo, Prishtina, Kosovo
2 Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
3 Division of Genetics, Wadsworth Center, New York State Department of Health, Albany, New York, United States
4 Medical Faculty, Saints Cyril and Methodius University, Skopje, Macedonia
5 Dr. Fran Mihaljevic University Hospital for Infectious Diseases, Zagreb, Croatia
Article information
  • Hepatitis Monthly: October 2018, 18 (10); e80189
  • Published Online: October 14, 2018
  • Article Type: Research Article
  • Received: June 5, 2018
  • Revised: September 5, 2018
  • Accepted: September 28, 2018
  • DOI: 10.5812/hepatmon.80189

To Cite: Jakupi X, M. Lunar M, Mlakar J, Matković I, P. Tavakoli N, et al. HCV Infection among Injecting Drug Users in Prishtina, Kosovo, Hepat Mon. 2018 ; 18(10):e80189. doi: 10.5812/hepatmon.80189.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-62. [PubMed: 2523562].
  • 2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41. [PubMed: 17552026]. [PubMed Central: PMC4146761].
  • 3. Blach S, Zeuzem S, Manns M, Altraf I, Dubrog AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
  • 4. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV virus taxonomy profile: flaviviridae. J Gen Virol. 2017;98(1):2-3. doi: 10.1099/jgv.0.000672. [PubMed: 28218572]. [PubMed Central: PMC5370391].
  • 5. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol. 2015;53(3):967-72. doi: 10.1128/JCM.02831-14. [PubMed: 25520447]. [PubMed Central: PMC4390628].
  • 6. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599]. [PubMed Central: PMC4303918].
  • 7. WHO. Global hepatitis report 2017. Geneva: World Health Organization. 2017, [cited May 2018]. Available from: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
  • 8. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0. [PubMed: 21802134]. [PubMed Central: PMC3285467].
  • 9. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181. doi: 10.1186/1471-2334-13-181. [PubMed: 23597411]. [PubMed Central: PMC3716892].
  • 10. ECDC. Systematic review on hepatitis B and C prevalence in the EU/EEA. Stockholm: European Centre for Disease Prevention and Control. 2016, [cited May 2018]. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf.
  • 11. Institute of Public Health. Albania Behavioural and Biological Surveillance Study (Bio-BSS) Report; "third round.". Tirana: Institute of Public Health; 2011.
  • 12. Institute for Public Health FB and H. A respondent-driven sampling survey—behavioral and biological surveillance study among injection drug users in Bosnia and Herzegovina. Sarajevo; 2012.
  • 13. Lausevic D, Begic S, Mugosa B, Terzic N, Vratnica Z, Labovic I, et al. Prevalence of HIV and other infections and correlates of needle and syringe sharing among people who inject drugs in Podgorica, Montenegro: a respondent-driven sampling survey. Harm Reduct J. 2015;12:2. doi: 10.1186/s12954-015-0039-0. [PubMed: 25884194]. [PubMed Central: PMC4367921].
  • 14. Institute of Public Health of Republic of Macedonia. Report on the bio-behavioral study among people who inject drugs in Macedonia, 2014. Skopje: Ministry of Health of Republic of Macedonia; 2014.
  • 15. EMCDDA. Serbia country overview. Lisbon: European Monitoring Center for Drugs and Drug Addiction. 2015, [cited October 2017]. Available from: http://www.emcdda.europa.eu/countries/serbia.
  • 16. KAS. Kosovo census atlas. Pristina, Kosovo Agency of Statistics. 2013, [cited October 2017]. Available from: http://ask.rks-gov.net/media/2009/kosovo-census-atlas-2011.pdf.
  • 17. National Institute of Public Health of Kosovo. Programmatic mapping and size estimations of key populations in Kosovo. 2016, [cited October 2017]. Available from: http://ghdx.healthdata.org/geography/kosovo.
  • 18. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201-7. [PubMed: 8968908]. [PubMed Central: PMC229539].
  • 19. Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 2004;32(Web Server issue):W654-9. doi: 10.1093/nar/gkh419. [PubMed: 15215470]. [PubMed Central: PMC441557].
  • 20. HCV Sequence Alignments. Sequence alignments - Los Alamos HCV database. 2018. Available from: http://hcv.lanl.gov/content/sequence/NEWALIGN/align.html.
  • 21. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, et al. European and Italian seroconverter studies. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004;189(2):292-302. doi: 10.1086/380821. [PubMed: 14722895].
  • 22. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999;41:95–8.
  • 23. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9. doi: 10.1093/molbev/msr121. [PubMed: 21546353]. [PubMed Central: PMC3203626].
  • 24. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-402. [PubMed: 9254694]. [PubMed Central: PMC146917].
  • 25. Karlin S, Altschul SF. Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. Proc Natl Acad Sci U S A. 1990;87(6):2264-8. [PubMed: 2315319]. [PubMed Central: PMC53667].
  • 26. Karlin S, Altschul SF. Applications and statistics for multiple high-scoring segments in molecular sequences. Proc Natl Acad Sci U S A. 1993;90(12):5873-7. [PubMed: 8390686]. [PubMed Central: PMC46825].
  • 27. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307-21. doi: 10.1093/sysbio/syq010. [PubMed: 20525638].
  • 28. United Nations Office on Drugs and Crime. World drug report 2014. New York: United Nations Publications. 2014, [cited October 2017]. Available from: http://www.unodc.org/documents/wdr2014/World_Drug_Report_2014_web.pdf.
  • 29. Hysaj-Vila B, Shundi L, Basho M, Ali E, Abazaj E, Bino S, et al. Distribution of hepatitis C virus genotypes among injecting drug users in Albania. Alban Med J. 2014;4:73-6.
  • 30. Treso B, Takacs M, Dencs A, Dudas M, Par A, Rusvai E. Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill. 2013;18(47). pii: 20639. [PubMed: 24300886].
  • 31. Alavi SM, Behdad F. Seroprevalence study of hepatitis C and hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006). Hepat Mon. 2010;10(2):101-4. [PubMed: 22312381]. [PubMed Central: PMC3270351].
  • 32. Backmund M, Meyer K, Wachtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol. 2003;18(6):563-8. [PubMed: 12908723].
  • 33. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health. 2006;6:229. doi: 10.1186/1471-2458-6-229. [PubMed: 16970811]. [PubMed Central: PMC1586015].
  • 34. De P, Cox J, Boivin JF, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102(11):1730-9. doi: 10.1111/j.1360-0443.2007.01936.x. [PubMed: 17935581].
  • 35. Brewer DD, Hagan H, Sullivan DG, Muth SQ, Hough ES, Feuerborn NA, et al. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J Infect Dis. 2006;194(6):764-72. doi: 10.1086/505585. [PubMed: 16941342].
  • 36. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010;202(7):984-90. doi: 10.1086/656212. [PubMed: 20726768]. [PubMed Central: PMC2932767].
  • 37. Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis. 2011;204(12):1830-8. doi: 10.1093/infdis/jir535. [PubMed: 22013220]. [PubMed Central: PMC3247810].
  • 38. EMCDDA. National report 2014: Kosovo. Lisbon: European Monitoring Centre for Drugs and Drug Addiction. 2014, [cited October 2017]. Available from: http://www.emcdda.europa.eu/countries/kosovo.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments